TruScreen is focused on the effective commercialisation of its second-generation TruScreen2 optoelectronic cervical cancer screening device, which has already been launched in key target markets. The device provides objective and real-time cervical cancer screening assessments and requires only limited training for the operator, which makes it well-suited for developing countries.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.